JP2017526689A5 - - Google Patents

Download PDF

Info

Publication number
JP2017526689A5
JP2017526689A5 JP2017511914A JP2017511914A JP2017526689A5 JP 2017526689 A5 JP2017526689 A5 JP 2017526689A5 JP 2017511914 A JP2017511914 A JP 2017511914A JP 2017511914 A JP2017511914 A JP 2017511914A JP 2017526689 A5 JP2017526689 A5 JP 2017526689A5
Authority
JP
Japan
Prior art keywords
dengue
composition
virus
use according
serotype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017511914A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526689A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/070060 external-priority patent/WO2016034629A1/en
Publication of JP2017526689A publication Critical patent/JP2017526689A/ja
Publication of JP2017526689A5 publication Critical patent/JP2017526689A5/ja
Pending legal-status Critical Current

Links

JP2017511914A 2014-09-02 2015-09-02 デング熱ウイルス病に対するワクチン組成物 Pending JP2017526689A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14306350.1 2014-09-02
EP14306350 2014-09-02
EP15305851.6 2015-06-04
EP15305851 2015-06-04
PCT/EP2015/070060 WO2016034629A1 (en) 2014-09-02 2015-09-02 Vaccine compositions against dengue virus diseases

Publications (2)

Publication Number Publication Date
JP2017526689A JP2017526689A (ja) 2017-09-14
JP2017526689A5 true JP2017526689A5 (OSRAM) 2018-10-11

Family

ID=54064325

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017511914A Pending JP2017526689A (ja) 2014-09-02 2015-09-02 デング熱ウイルス病に対するワクチン組成物

Country Status (14)

Country Link
US (1) US10946087B2 (OSRAM)
EP (1) EP3188751A1 (OSRAM)
JP (1) JP2017526689A (OSRAM)
KR (2) KR20170043660A (OSRAM)
CN (1) CN106999564A (OSRAM)
AU (1) AU2015310951A1 (OSRAM)
BR (1) BR112017004197A2 (OSRAM)
CA (1) CA2958949A1 (OSRAM)
MX (1) MX2017002794A (OSRAM)
MY (1) MY192739A (OSRAM)
PH (1) PH12017500304A1 (OSRAM)
SG (1) SG11201701256RA (OSRAM)
TW (1) TWI852899B (OSRAM)
WO (1) WO2016034629A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102389908B1 (ko) 2013-03-15 2022-04-26 다케다 백신즈 인코포레이티드 백신 내의 뎅기 바이러스 키메라 구조체를 위한 조성물 및 방법
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
KR102611235B1 (ko) * 2016-04-13 2023-12-08 다케다 백신즈 인코포레이티드 어린이 및 젊은 성인에서 뎅기 바이러스에 대한 백신접종 조성물 및 방법
US11531029B2 (en) 2017-05-08 2022-12-20 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods and compositions for the detection of flavivirus infections
JP7313345B2 (ja) 2017-10-05 2023-07-24 サノフィ・パスツール デング熱に対するブースターワクチン接種のための組成物
US11464815B2 (en) * 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
ES2908304T3 (es) 2018-09-05 2022-04-28 Takeda Vaccines Inc Dosis unitaria de vacuna contra el dengue y administración de la misma
PH12022550261A1 (en) 2019-08-16 2023-06-26 Takeda Vaccines Inc Methods for preventing dengue and hepatitis a
WO2025072259A1 (en) 2023-09-25 2025-04-03 Takeda Vaccines, Inc. Coadministration of tetravalent dengue vaccine with hpv vaccine

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741077B1 (fr) * 1995-11-14 1998-01-23 Pasteur Institut Vaccin polyvalent anti-dengue
US6962708B1 (en) 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
ES2244050T3 (es) 1997-02-28 2005-12-01 Acambis Inc. Vacunas quimericas de flavivirus.
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
WO2001039802A1 (en) 1999-12-01 2001-06-07 Oravax, Inc. Chimeric flavivirus vaccines
WO2001060847A2 (en) 2000-02-16 2001-08-23 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Avirulent, immunogenic flavivirus chimeras
US7569383B2 (en) 2001-06-01 2009-08-04 Acambis Inc. Chimeric flavivirus vectors
US20050002968A1 (en) 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
EP2295023A1 (en) 2002-01-15 2011-03-16 Sanofi Pasteur Biologics Co. Flavivirus vaccines
AU2003239932A1 (en) 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
MX2007015872A (es) 2005-06-17 2008-04-21 Sanofi Pasteur Cepa atenuada del serotipo 2 del dengue.
CA2611934C (en) 2005-06-17 2015-11-03 Sanofi Pasteur Dengue serotype 1 attenuated strain
AU2006315026B2 (en) 2005-11-21 2012-11-22 Sanofi Pasteur Limited Stabilizing formulations for recombinant viruses
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
US7968102B2 (en) 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
FR2903605A1 (fr) 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
WO2008115314A2 (en) 2007-01-31 2008-09-25 Sanofi Pasteur Biologics Co. Flavivirus vaccine vector against influenza virus
US8715689B2 (en) 2008-04-30 2014-05-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Chimeric west nile/dengue viruses
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
US8968996B2 (en) * 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
WO2011013097A2 (en) 2009-07-29 2011-02-03 Bernd Helmut Adam Rehm Polymer particles and uses thereof
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
MX2012012681A (es) 2010-05-21 2012-12-17 Univ Pittsburgh Secuencias del virus de dengue universales y metodos de uso.
WO2012051491A1 (en) 2010-10-14 2012-04-19 The United States Of America, As Represented By The Secretary National Institutes Of Health Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting
ITMI20121231A1 (it) * 2012-07-16 2014-01-17 St Microelectronics Srl Metodo di controllo burst-mode per basso consumo in ingresso in convertitori risonanti e relativo dispositivo di controllo
WO2014016362A1 (en) * 2012-07-24 2014-01-30 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
MY168959A (en) 2012-07-24 2019-01-28 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
WO2017005654A1 (en) * 2015-07-03 2017-01-12 Sanofi Pasteur Concomitant dengue, diphtheria, tetanus, whooping cough (pertussis), polio, and haemophilus influenzae type b vaccination.

Similar Documents

Publication Publication Date Title
JP2017526689A5 (OSRAM)
JP2015524421A5 (OSRAM)
Yong et al. Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus
JP2015524422A5 (OSRAM)
Modjarrad MERS-CoV vaccine candidates in development: The current landscape
RU2017113571A (ru) Рекомбинантные вакцины от fmdv и их применение
HK1246658A1 (zh) 猪流行性腹泻病毒品种及其免疫原性组合物
MX2013004159A (es) Proteina vp6 de la capside de norovirus y de rotavirus para el uso como vacuna combinada.
JP2016508999A5 (OSRAM)
JP2017502662A5 (OSRAM)
WO2017156511A8 (en) Live attenuated zika virus vaccine
Pripuzova et al. Exploring of primate models of tick-borne flaviviruses infection for evaluation of vaccines and drugs efficacy
WO2013001285A3 (en) Fmdv vp1 peptides
JP2013523783A5 (OSRAM)
JP2019511221A5 (OSRAM)
JP2016504315A5 (OSRAM)
JP2018500878A5 (OSRAM)
CO6541529A2 (es) Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quimericos
Umar et al. Emerging threat of H9N2 viruses in poultry of Pakistan and vaccination strategy
PH12017500216A1 (en) Vaccine in serotype-9 fowl adenovirus recombinant vector
JP2016528176A5 (OSRAM)
WO2014140166A3 (en) Vaccine
Zhang et al. Hexon-modified recombinant E1-deleted adenoviral vectors as bivalent vaccine carriers for Coxsackievirus A16 and Enterovirus 71
WO2018066999A3 (en) Chimeric enterovirus virus-like particles
Kim et al. Cross-protective immune responses elicited by a Korean variant of infectious bronchitis virus